Chiara Borsari

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 27

Top Topics

Molecular Docking

Trypanosoma Cruzi

Top Venues

Journal of medicinal chemistry

Chemical science

ACS infectious diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Michele Mari, Caroline Lanthier, Matic Proj, Etienne J Donckele, Laia Josa-Culleré, Kristina Goncharenko, Salomé Leroy, Brieuc Matagne, Sean M McKenna, Chiara Borsari
Boosting the Impact of EFMC Young Scientists Network Through the Creation of Working Groups. ChemMedChem (2024)
Alexandra Ioana Corfu, Nuno Santarem, Sara Luelmo, Gaia Mazza, Alessandro Greco, Alessandra Altomare, Giulio Ferrario, Giulia Nasta, Oliver Keminer, Giancarlo Aldini, Lucia Tamborini, Nicoletta Basilico, Silvia Parapini, Sheraz Gul, Anabela Cordeiro-da-Silva, Paola Conti, Chiara Borsari
Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents. ACS infectious diseases (2024)
Alexandra Ioana Corfu, Nuno Santarem, Sara Luelmo, Gaia Mazza, Alessandro Greco, Alessandra Altomare, Giulio Ferrario, Giulia Nasta, Oliver Keminer, Giancarlo Aldini, Lucia Tamborini, Nicoletta Basilico, Silvia Parapini, Sheraz Gul, Anabela Cordeiro-da-Silva, Paola Conti, Chiara Borsari
Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents. ACS infectious diseases 10 (6) (2024)
Aleksandra Baranczak, Simone V Bigi-Botterill, Chiara Borsari, Amanda W Dombrowski, Michelle A Estrada, Mark P Farrell, Andrew P Riley, John G Woodland
Announcing the Early Career Board of ACS Medicinal Chemistry Letters . ACS medicinal chemistry letters 15 (9) (2024)
Ricardo A M Serafim, Alexander Titz, Chiara Borsari
Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Ricardo A M Serafim, Alexander Titz, Chiara Borsari
Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Michele Mari, Caroline Lanthier, Matic Proj, Etienne J Donckele, Laia Josa-Culleré, Kristina Goncharenko, Salomé Leroy, Brieuc Matagne, Sean M McKenna, Chiara Borsari
Boosting the Impact of EFMC Young Scientists Network Through the Creation of Working Groups. ChemMedChem 19 (15) (2024)
Lori Ferrins, Margaret E Olson, Krupanandan Haranahalli, Melissa C Grenier-Davies, Matthew W Boudreau, Brieuc Matagne, Etienne J Donckele, Chiara Borsari
YMCC and YSN: An Opportunity for Scientific and Cultural Exchange. Journal of medicinal chemistry (2023)
Werner Theodor Jauslin, Matthias Schild, Thorsten Schaefer, Chiara Borsari, Clara Orbegozo, Lukas Bissegger, Saule Zhanybekova, Danilo Ritz, Alexander Schmidt, Matthias P Wymann, Dennis Gillingham
A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα. Chemical science 15 (2) (2023)
Lori Ferrins, Margaret E Olson, Krupanandan Haranahalli, Melissa C Grenier-Davies, Matthew W Boudreau, Brieuc Matagne, Etienne J Donckele, Chiara Borsari
YMCC and YSN: An Opportunity for Scientific and Cultural Exchange. ACS medicinal chemistry letters 14 (9) (2023)
Werner Theodor Jauslin, Matthias Schild, Thorsten Schaefer, Chiara Borsari, Clara Orbegozo, Lukas Bissegger, Saule Zhanybekova, Danilo Ritz, Alexander Schmidt, Matthias P Wymann, Dennis Gillingham
A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα. Chemical science 15 (2) (2023)
Werner Theodor Jauslin, Matthias Schild, Thorsten Schaefer, Chiara Borsari, Clara Orbegozo, Lukas Bissegger, Saule Zhanybekova, Danilo Ritz, Alexander Schmidt, Matthias P Wymann, Dennis Gillingham
A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα. Chemical science 15 (2) (2023)
Andrea Galbiati, Aureliano Zana, Chiara Borsari, Marco Persico, Stefania Bova, Oleh Tkachuk, Alexandra Ioana Corfu, Lucia Tamborini, Nicoletta Basilico, Caterina Fattorusso, Stefano Bruno, Silvia Parapini, Paola Conti
Role of Stereochemistry on the Biological Activity of Nature-Inspired 3-Br-Acivicin Isomers and Derivatives. Molecules (Basel, Switzerland) 28 (7) (2023)
Chiara Borsari, Erhan Keles, Jacob A McPhail, Alexander Schaefer, Rohitha Sriramaratnam, Wojciech Goch, Thorsten Schaefer, Martina De Pascale, Wojciech Bal, Matthias Gstaiger, John E Burke, Matthias P Wymann
Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα. Journal of the American Chemical Society 144 (14) (2022)
George E Magoulas, Pantelis Afroudakis, Kalliopi Georgikopoulou, Marina Roussaki, Chiara Borsari, Theano Fotopoulou, Nuno Santarem, Emile Barrias, Paloma Tejera Nevado, Julia Hachenberg, Eugenia Bifeld, Bernhard Ellinger, Maria Kuzikov, Irini Fragiadaki, Effie Scoulica, Joachim Clos, Sheraz Gul, Maria Paola Costi, Wanderley de Souza, Kyriakos C Prousis, Anabela-Cordeiro da Silva, Theodora Calogeropoulou
Design, Synthesis and Antiparasitic Evaluation of Click Phospholipids. Molecules (Basel, Switzerland) 26 (14) (2021)
Chiara Borsari, Erhan Keles, Andrea Treyer, Martina De Pascale, Paul Hebeisen, Matthias Hamburger, Matthias P Wymann
Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability. RSC medicinal chemistry 12 (4) (2021)
Chiara Borsari, Martina De Pascale, Matthias P Wymann
Chemical and Structural Strategies to Selectively Target mTOR Kinase. ChemMedChem 16 (18) (2021)
Manoj K Rathinaswamy, Zied Gaieb, Kaelin D Fleming, Chiara Borsari, Noah J Harris, Brandon E Moeller, Matthias P Wymann, Rommie E Amaro, John E Burke
Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. eLife 10 (2021)
Carolina B Moraes, Gesa Witt, Maria Kuzikov, Bernhard Ellinger, Theodora Calogeropoulou, Kyriakos C Prousis, Stefano Mangani, Flavio Di Pisa, Giacomo Landi, Lucia Dello Iacono, Cecilia Pozzi, Lúcio Holanda Gondim de Freitas-Júnior, Bruno Dos Santos Pascoalino, Claudia P Bertolacini, Birte Behrens, Oliver Keminer, Jennifer Leu, Markus Wolf, Jeanette Reinshagen, Anabela Cordeiro-da-Silva, Nuno Santarem, Alberto Venturelli, Stephen Wrigley, Deepa Karunakaran, Bethlehem Kebede, Ina Pöhner, Wolfgang Müller, Joanna Panecka-Hofman, Rebecca C Wade, Martina Fenske, Joachim Clos, José María Alunda, María Jesús Corral, Elisa Uliassi, Maria Laura Bolognesi, Pasquale Linciano, Antonio Quotadamo, Stefania Ferrari, Matteo Santucci, Chiara Borsari, Maria Paola Costi, Sheraz Gul
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. SLAS discovery : advancing life sciences R & D 24 (3) (2020)
Chiara Borsari, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker, Lukas Bissegger, Martina De Pascale, Anna Melone, Rohitha Sriramaratnam, Florent Beaufils, Matthias Hamburger, Paul Hebeisen, Wolfgang Löscher, Doriano Fabbro, Petra Hillmann, Matthias P Wymann
4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. Journal of medicinal chemistry 63 (22) (2020)
Chiara Borsari, Darci J Trader, Annalisa Tait, Maria Paola Costi
Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology. Journal of medicinal chemistry 63 (5) (2020)
Denise Rageot, Thomas Bohnacker, Erhan Keles, Jacob A McPhail, Reece M Hoffmann, Anna Melone, Chiara Borsari, Rohitha Sriramaratnam, Alexander M Sele, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, John E Burke, Matthias P Wymann
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. Journal of medicinal chemistry 62 (13) (2019)
Davide Vanossi, Monica Caselli, Giorgia Pavesi, Chiara Borsari, Pasquale Linciano, Maria Paola Costi, Glauco Ponterini
Excited-state intramolecular proton transfer in a bioactive flavonoid provides fluorescence observables for recognizing its engagement with target proteins. Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology 18 (9) (2019)
Chiara Borsari, Denise Rageot, Alix Dall'Asen, Thomas Bohnacker, Anna Melone, Alexander M Sele, Eileen Jackson, Jean-Baptiste Langlois, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, Matthias P Wymann
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. Journal of medicinal chemistry 62 (18) (2019)
Elisa Uliassi, Lorna Piazzi, Federica Belluti, Andrea Mazzanti, Marcel Kaiser, Reto Brun, Carolina Borsoi Moraes, Lúcio Holanda Gondim de Freitas-Júnior, Sheraz Gul, Maria Kuzikov, Bernhard Ellinger, Chiara Borsari, Maria Paola Costi, Maria Laura Bolognesi
Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections. ChemMedChem 13 (7) (2018)
Denise Rageot, Thomas Bohnacker, Anna Melone, Jean-Baptiste Langlois, Chiara Borsari, Petra Hillmann, Alexander M Sele, Florent Beaufils, Marketa Zvelebil, Paul Hebeisen, Wolfgang Löscher, John E Burke, Doriano Fabbro, Matthias P Wymann
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. Journal of medicinal chemistry 61 (22) (2018)
Florent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, Thomas Bohnacker, Anna Melone, Romina Marone, Eileen Jackson, Xuxiao Zhang, Alexander Sele, Chiara Borsari, Jürgen Mestan, Paul Hebeisen, Petra Hillmann, Bernd Giese, Marketa Zvelebil, Doriano Fabbro, Roger L Williams, Denise Rageot, Matthias P Wymann
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Journal of medicinal chemistry 60 (17) (2017)